>> they got no respect and frankly it's because of the management team. they have a lot of things there. great software, great balance sheet but they get no respect. >> quick final my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. hey, i'm cramer! welcome to "mad money." welcome to cramerica. i'm just trying make you a little money. my job is not just to entertain you but to educate you, too. call me at 1-800-743-cnbc. unless you're a bowler, you have no idea what the heck it means when i say this market has got

some of the best pin action i have ever seen. i can't take you to the lanes, i can't form a league with you, i can't even share my psych delically laced bowling shoes with you. but the s&p jumping 1.25%, nasdaq falling 1.36%. by golly, i'm going to get you a shirt, a ball and a couple of lanes. we are rolling strikes. this pin smashes into the head pin and sends the rest shattering. today we had more pin action than the plaza lanes in madison, new jersey. and i felt like it was like the

old days when i donned my bowling shirt, brought my own ball and played with style. let's go over some of the strikes this market rolled because this one felt pretty darn perfect from start to finish. no, check that, from before the start to the finish. much of the action started overseas the night before where we've become so used to getting bad news. that's right. before we even opened for trading, you knew it was going to be a good one from the number, 50.3. that's the number china's industrial pmi or its gauge of strength hit last night and the number the eurozone came out with. yup, an odd coincidence. but remember, 50 is the fullcrum. given that we expected contractions with both numbers, the gains, they were

instantaneous. more months the worst performing have been the big mining metals because china is knee deep in all of those things. and you know what? for a while they were running lean but they don't need any of this stuff. in fact, the smart money, the hedge managers have been knocking and shorting everything that can possibly be used to build anything in china. that's been going on for months now. doesn't get me wrong, it has been a terrific trade. but when you get any number but particularly this number out of china last night, get out of the way because the pin action, it is phenomenal! caterpillar has been among the worst performing fund in the dow. the manager came to cnbc

conference and said his favorite was caterpillar because they placed such a big bet on china and had come up snake eyes. he stressed the big commodity super cycle, they were kaput. secular decline. curse words when it comes to stocks. i have to tell you, i'm not disagreeing with him. i think the mineral plays peaked in 2008 when china was still smoking doesn't make much sense at all now and they've been the bain of my existence when it comes to charitable trust. i think cat makes the best machines but sadly cat no executing. however, today for once if you owned the stocks, you didn't roll a gutter ball. in fact, caterpillar thread the group along with cummins. so many bowlers were caught leaning the wrong way, short selling bowlers, they might as well have been knocking down some long necks in the bar

behind the lanes. i think i saw some bears roll the ball into the gutter into the next aisle! fine guys. europe has been such a disappointment. you buy everything from the european bags from the american-based companies like the autos. globals pulls up more than the minerals, gets the oils to roll strike after strike. how about the fact that exxon, the biggest of the oils, reported a terrible number, yet the whole group saved exxon and another terrible reporter, royal dutch soared in fashion. what kind of day was today? pioneer natural in news stemming from the old fashioned permian basin, any oil with permian

construction, even lowly worm chesapeake reported a good number, a strike right down the middle for once. and the stock closed at 24.95. if you want to see a bowler's paradise being look at the weekly unemployment claims roll, the strongest number since 2008. given that the fed said it's on hold just the other day, this number was perfect, gave you confidence the economy was indeed getting strongstronger, means earnings could be stronger than what we're seeing. and we got our own pmi and it was much better than expected. when the economy is humming, what flies? the transports go flying. they're knocking down pins left and right. the market had been pretty darn doggy of late, not confirming so to speak. the action in the rails, which

had been stalled because of disappointing earnings from the rails for us commerce loving rail people. when jobless claims come down, spending goes higher. one of the most amazing first days we've had in ages. sprouts farmers market priced at 18, opened at 35 and rallied further to 40, more than doubling right off the bat, what a command performance, one that stole the show from whole foods. low claims means fewer loan losses for the banks and that group rolled its best game in months and it looks like jp morgan is moving to much higher levels. pity those who sold it when they had that whale problem. if you wanted to see pin action, look to further than the social, mobile and cloud space -- ♪

hallelujah ♪ -- yelp may be the new key to this market. and phase tried to mount that dastardly 38 level. facebook continued its relentless drive toward its all-time high, stopping just $2 short of their goal. anything that even looked like yelp bolted higher today. how about helping you find your dream home, trulia, zillow. marketo, finished up 1.58 and after the bell linked-in, the

social networking web site packed on another 10 after reporting a magnificent quarter. the ambassador was breathtaking. along with so many different lanes that swept up all kinds of companies, including some that were expected to be disappointing. remember federal express, amazon, netflix increased, not just because "breaking bad" is going to start august 11th. it was one remarkable session. it reminded us once more that the brilliant minds who say you can't buy stocks and preach endless cautions as they talk about tapering. pessimists keep getting blindsided, the bears smacked by stampeding bulls. the bottom line, this month of august started off just like the last month finished, just remarkable with a roar. it's as if the whole lane bowled above its head where nine was an embarrassment and a spare wasn't much better.

it was a confirmation once again those who believe things are better -- like i say, they're rolling 300 and those who think things are worse, gutter over and over again. the only answer for those of us parents out there is to brings bumpers normally reserved to the eight and under crowd to the bear's den because they can't play to save their lives. nate in california, please. nate. >> caller: jim, nate bringing you a big california booyah. >> what's shaking, partner! >> caller: visa is what's shaking. we got lawsuits, all that good stuff. i want to hear from the man is it speculative or is it warrant sfd. >> >> the money is all going to mastercard. it's now ready to roar again. i think visa had a good quarter

and is well managed. i like visa. tim in california, please. >> caller: tim here, wondering about taser. >> we're in a market where really great companies report good numbers, i'm talking about the 3m ilk, they go higher. the tasers, too speculative for these guys. august came in like a lion, the market roar is on and the pin action gets downright amazing! stay with cramer! coming up, earnings avalanche. the season's in high gear and tonight cramer's got a triple shot of ceo exclusives to keep you ahead of the game. first up, botox maker allergan stock is flat for the year while the rest of the market has been

soaring. will that frown be turned upside down and give you an injection of profits? and marquetto catapulted yesterday on a strong quarter. have you missed the rise or is now the time to get in? plus it was once thought impossible in the medical industry, but could it work miracles on your portfolio? and later, need some yelp? it's the holy trinity, cloud, mobile and social. but cramer's full review includes something you wouldn't expect, all coming up on "mad money." don't miss a second of "mad money." follow @jimcramer on twitter, send jim an e-mail or give us a call at 1-800-743-cnbc.

miss something? head to madmoney.cnbc.com.

get on board for better sleep. it's sleep train's interest-free for 3 event! get 3 years interest-free financing on beautyrest black, stearns & foster, serta icomfort, even tempur-pedic. plus, get free delivery and sleep train's 100-day low price guarantee. you'll never find an interest rate lower than sleep train's interest-free for 3 event, on now! superior service, best selection, lowest price, guaranteed! ♪ sleep train ♪ your ticket to a better night's sleep ♪

is allergan finally ready to rebound? we've liked the stock for a long time on "mad money." but the last time allergan reported, the company announced a key product in its pipeline for macular degeneration needed additional work that would delay potential approval. the stock got slammed. then in june we learned allergan's second biggest drug for dry eye might face generic competition sooner than expected. today it inched up slightly, after putting up a better than expected quarter. it delivered a 2 cent earnings beat and revenues exceeded expectations. it was clear many questions remain. has allergan gotten its groove

back? let's find back with david pyatt, the chairman of al are began. welcome back to "mad money." >> thanks for having me back, jim. let's start with the company's performance. it's performing really well right now. we had good top line growth, over 10% we have about 16% in the second quarter, year to date 17%. so everything's looking good. we exceeded guidance expected by wall street on every almost every front. and we had eight fda approvals since 2010 and about four more approvals on horizon for the next year or so. things look great. >> you said in the conference call we've got some challenges. one is the drugs restasis, that

you may have some generic challenges. tell our viewers what you have in mind if things don't go allergan's way. >> absolutely. so let's first of all ground ourselves. restasis is the on approved drug in the united states for they e therapeutic dry eye, headed rapidly toward $1 billion in sales, which makes it the largest non-retina drug in the market. we were somewhat surprised that fda put out guidance for public comment on a potential generic pathway. very unusual. they asked for comment upon doing effectively in test tube assays instead of doing clinical trials. fda to our knowledge has never approved a so-called emulsion eye drop in its try. emulsion is a mixture of oil and

water and we all learned in school that's verically complic to suspend such a product in a bottle, let alone in your eye. of course in doing all this one has to keep patient safety very much in mind because it will be terrible if a patient were to lose their vision or let alone completely their sight. >> what's interesting is i think you've always been straight with us, straight with everybody and yet these analysts on the conference call and the stock reflects the fact that people feel you can't stop this, that it is going to happen no matter what. what you just described will be a reason that would be foolish to go right into a generic version. >> of course we've dealt historically with the scientists, these are the people who approve the drugs.

you may remember long ago we had our own challenges getting restasis approved some ten years ago. no other product ever approved since then. so now of course we have to work with the generics division, who have a different mission. their job is to reduce the cost of public health care, which we understand. many of our drugs have been genericized appropriately and now we have to say to the generics division, maybe you have to be careful here. taking shortcuts could be quite dangerous. >> in the regeneron project, a the lo of people were upset your stock was in high hundreds, 110. you now said there was a delay. it now seems like you're now ahead of where we first thought you would be when you first announced that delay. am i reading that correctly, that maybe you're closer than having a product than two quarters ago? it could be something that's better than we think? >> obviously that's our job.

so really my job is with our scientists is to show that darpin is delayed and very much not dead. most people thought it could be approved on the market by 2017. basically we said this could be fractionally delayed, up to 2018, 2019. and since three months ago we lost no time. we're already recruiting patients into the next trial. now, what have we changed? the first time around it would be quite unethical to force physicians to keep patients in the trial for a long time if they weren't convinced about either the safety or more significantly the efficacy of the drug. having had the readout from that last trial, we've now designed this current one where we're going to get a much better

readout. and they have picked up steam so fast on the original incumbent based on similar efficacy but slightly longer duration. if we can do that again, we have absolutely gigantic product on our hand. just to put it in context, the world's retina market today is about $5 billion and growing in excess of 20% per year. >> i think you've answered both those. i want to circle back to the drug that seems to be doing fabulously. all the botox indications you've talked about are above planned from when you were on last. is that true? >> botox is performing very well. and of course this a product with enormous carry because we are creating new market segments, chronic migraines, bladder spasity. i'm always a little delayed

because i have to look at the market competitor information. the world market 15% year over year and we grew 16%. so we actually gained share across the board. that's amazing when you think botox, with all of its competition around the world, we're very close to 80% of the world market in value. >> okay, david. thank you. you've been, again, always straight forward. the challenges are there. i think the opportunities are not in the stock. i want to thank you for coming on, david pyott, chairman and ceo of allergan. >> the stock reflects neither this drug that is ahead of plan nor the genetic. i'm with him. >> coming up, need some yelp? it's the holy trinity, cloud, mobile and social and yelp's got

it. after beating the street, shares are flying. but cramer's full review includes something you won't expect. don't miss it next. clients are always learning more to make their money do more. (ann) to help me plan my next move, i take scottrade's free, in-branch seminars... plus, their live webinars. i use daily market commentary to improve my strategy.

and my local scottrade office guides my learning every step of the way. because they know i don't trade like everybody. i trade like me. i'm with scottrade. (announcer) scottrade... ranked "highest in customer loyalty for brokerage and investment companies."

[ male announcer ] it's a golden opportunity to discover a hybrid from the luxury car company that understands that one type of hybrid isn't right for everyone. come to the lexus golden opportunity sales event and choose from one of five lexus hybrids that's right for you, including the lexus es and ct hybrids. ♪ who has mastered mobile? who can make money in mobile advising and not be crushed by the cheap commodityized ad rallies? and now as of last night we

discovered that yelp can do. yelp is thriving with second quarter sales up 69% on special nic initiatives that make mobile better for review and spend site. review and spend. what does that mean? it's my term but it's what you do when you yelp! you hit up yelp, you find out what people say, you read the ads and then you go spend money at that advertiser. with huge retention, the site is a winner for advertisers and for yelp itself. it's introducing a function for people to access and where you can tap in on what you know people like about certain this evenings. only a handful of companies have offerings that address all

three, salesforce.com, a yelp partner. it started in 2004 with two employees and an office in san francisco to sell services to small and medium sized business just to that city, then rolled out to chicago, went national, went international. it was a considerable rollout, five new cities, then seven but now they're in 97 and it's 30 million to date. the reviewers create the content, not yelp and advertisers pay yelp to follow up on the leads. as more and more viewers come on, it becomes incredibly important for the company being reviewed to have a presence on yelp. and buying advertising on yelp is an easy process. and it improves on the yellow majors. yelp has morphed into the mobile

yellow pages, kind of the poster boy for the activity. think of it, can you imagine carrying around the old yellow pages? you would get a darn hernia. the advertisers stand to win big here. you're meaning the traffic that you already know is interested in coming to your company at that moment. it's a remarkably powerful and robust concept. if you get new business formation, yelp should be able to leverage its model to huge success and profitability. it's still losing money, penny per share a quarter, though much less than the 4 cents analysts suspected. it's got a partnership with apple that's working well. apple need as better social and mobile strategy. it would cost apple a pittance to buy yelp and it would be the platform apple needs to protect its flank from facebook and

google. it simply must be bought by a company that needs this yellow pages of the future and apple makes the most sense to do so. there are two ways to win here, people. there's the oxygenated growth and then there's the takeover. that's the yelp story after this remarkably robust quarter. i want to go to juan in florida, please. juan. >> caller: booyah, jim. >> booyah, juan. >> wanted to ask you about oracle, orcl. their fourth quarter they disappointed us citing macro economic sources. but now that other companies like ibm have cited similar issues with macro economic forces, do you believe it's time to get back into oracle? >> i like their new partner salesforce.com more than i like oracle. sometimes i wonder allowed why did oracle not make their quarters? it puzzles me because i think it

should have made them given how robust their business is supposed to be. >> let's go to varun in michigan. >> caller: shouldn't apple acquire a company to bring in voice tech? >> i don't think they need to. they got everything they need from nuance. searching for profits right in your neighborhood? yelp is winning, hyper growth, possible takeover and now you know what it means to yelp! stay with cramer. tomorrow kick off the trading day with "squawk on the street," live at post nine. >> they're the best operator there is. people are slamming them. will you give me a break? give me a break!

[ male announcer ] i've seen incredible things. otherworldly things. but there are some things i've never seen before. this ge jet engine can understand 5,000 data samples per second. which is good for business. because planes use less fuel, spend less time on the ground and more time in the air. suddenly, faraway places don't seem so...far away. ♪

investors could lose tens of thousands of dollars on their 401(k) to hidden fees. is that what you're looking for, like a hidden fee in your giant mom bag? maybe i have them... oh that's right i don't because i rolled my account over to e-trade where... woah. okay... they don't have hidden fees... hey fern. the junk drawer? why would they... is that my gerbil? you said he moved to a tiny farm. that's it, i'm running away. no, no you can't come! [ male announcer ] e-trade. less for us. more for you.

it is time for the lightning round!

are you ready skedaddy? i'm going to start with david in wisconsin. david! dave! >> caller: yeah! >> hit me! >> caller: hey, jim. dqp. would you classify that as a forever stock? >> i said on twitter at jim kramer that the report this evening is they report tomorrow but it is a concept meaning don't play it for the quitter you either believe in it long term or you don't. warren in north carolina. warren! >> caller: booyah from wilmington, north carolina! >> they made a bond movie there. >> caller: they did. we are the hollywood of the east. >> you are, man. you are the beast of the east! what's up?

>> caller: i'm talking about dexcom. >> oh, the diabetes. i was looking at that this weekend. it's one of the good ones. that's a plus. jared in arizona. >> caller: how are you? a big booyah from scottsdale, arizona. my dad and i love your show. >> yes! >> caller: i want to thank you for everything. himx dropped popped about 10%. what do you think about these guys? is it a buy or sell? >> it's a buy. if google is using their technology, i'm not going to go against these guys. google is one of the four or five smartest companies on earth. i'm thumbs up on this. i need to go to nancy in new mexico. nancy. >> caller: booyah oh great wizard of wall street. >> wow, thank you.

>> caller: first i wanted to say thank you for everything you do. i had the pleasure of speaking you back in may regarding erickson and wanted to let you know all went well. my question is regarding pier one import, no short-term debt no, long-term debt, is this shackled to the home builder? >> it is still good. it is shackled to the home builders, but the home builders are going to be a great fourth quarter story and this one is really well run. we like the guy who runs it. he's always welcome on the show. tom in michigan. >> caller: hey, jim. booyah. >> booyah, tom. >> caller: what do you think of celldex. >> the stock has completely soared here. so take a snitsel.

go ahead, morgan. >> caller: my question is about sun power. i had a bullish call on it and it didn't go too well. what do you think is going on with this stock? >> no, you don't want to touch sunpower. i was willing to go with first solar because they did have a great conference call and great quarter. that's the only one i'm recommending. go for applied materials, they own a small sliver of that market. let's go to lois in florida. lois! >> caller: booyah, jim. we wanted to know is now the time to buy into chart industries? >> the stock is up like 16 straight points since they reported. if we don't wait for a pullback, i have to say if you haven't bought it yet, i am going to say it right here i think it's too late and it's got to come down. and that, ladies and gentlemen, is the conclusion of the

lightning round! >> the lightning round is sponsored by td ameritrade. [ male announcer ] time and sales data. split-second stats. [ indistinct shouting ] ♪ it's so close to the options floor... [ indistinct shouting, bell dinging ] ...you'll bust your brain box. ♪ all on thinkorswim from td ameritrade. ♪

never try to bet against the hottest, most powerful tech trend out there, particularly today. never bet against the a cloud, especially when it's integrated with social offerings. case in point, marketo, came public in may. they help clients streamline marketing decisions and build long-term relationships with their customers, especially social media. the stock did get slammed in may with the rest of the market. fast forward to this past tuesday. marketo reports after reports and blows away revenues. revenues up 62% on the year. 62%! this is now given you a terrific 45% gain since we interviewed the ceo back on june 10th, less than two months ago. let's check back in with mr.

john fernandez. mr. fernandez, thanks for being us. >> we're creating a product before everybody's eyes. there are skeptics and we're going to show them. >> you have the u as a customers. >> we're having this run in higher education, student recruitment and it's one more example of the different industries finding their way to what we're doing, from brands, business software -- >> are they trying to reach out

to certain students? are they doing e-mail campaign, twitter, facebook? a lot of people watch us -- have recently been students and they're trying to figure out where you are in that food chain. >> yes, yes and yes. if you're competing for students or customers in any industry, you're using us across all those channels. >> same thing with curves? >> same thing with curves, same thing with microsoft. >> you've become quite agnostic, working with microsoft but i didn't get the sense you're working with oracle. >> they've become one of our competitors. >> a lot of analysts question whether you'd be able to maintain, keep the relationship because you had a good relationship with salesforce.com. the people who were normally using you to exact target.

but that hasn't happened. >> it hasn't happened. so far we've just been thriving in the light of that. >> do we know whether anyone substantive that's important to you said we love the salesforce.com but we're going to have to leave you? >> i can't name one that's done that. >> this seems like a tipping point of major advertisers going social, mobile, going web, versus tv versus print. what happened to make it so it seems to flip so big? >> well, i think particularly as the social media properties have started to show advertising success and show they know how to monetize, you see a virtual cycle of beginning success, beginning success in every corner of this industry. >> one of the things you talked about, the so-called b to c, but

you've got this business to business. i'd like to use the example of lazar, an outfit, lazar asset management. who are they trying to connect to when they hire you? >> their capital markets people are trying to build relationships with buy side invest ooshs se investors, send their news letters out and build their brand identity because they're competing with goldman sachs or anybody else for mine share, using market technology to find new customers. >> you talk about how plain old fashioned e-mail may no longer be the way. is that internet one now, e-mail, and there's a lot more exciting ways to do things. >> you only have to move a quarter inch on an iphone and you're going from social media to other this evenings. so e-mail while it's fine is just one sliver of this world

that is social, mobile and everything going on at once. >> to me microsoft is sorely wanting in this area, they're partnered with you. microsoft calls you and says listen, marketo, salesforce we're mortal enemies with, we want to buy marketo. is it too early to sell? >> we're at the earliest, earliest days of a market and there's a very big company to be built here. i'm sure everybody's looking at that time. we'll do the right thing for shareholders but we hope to build a very big company. >> a lot of companies that come public, they do a gigantic equity offer. should our viewers be aware that anything can happen along those lines? that there might be a big equity offering? >> we're not planning anything like that. >> you don't need car of $100

million -- >> i any we're good. we're not planning any big equity offerings. >> do you have a lot of momentum and i've been recommending you since you went public. >> that's a good plan. >> it is a brave new world out there and only a couple companies have figured it out. the ones that have, they're like marketo, going higher. [ male announcer ] come to the golden opportunity sales event to experience the precision handling of the lexus performance vehicles, including the gs and all-new is.

♪ this is the pursuit of perfection. [ male announcer ] come to the golden opportunity sales event and experience the connectivity of the available lexus enform, including the es and rx. ♪ this is the pursuit of perfection. humans.

we are beautifully imperfect creatures living in an imperfect world. that's why liberty mutual insurance has your back, offering exclusive products like optional better car replacement, where if your car is totaled, we give you the money to buy one a model year newer. call... and ask an insurance expert about all our benefits today, like our 24/7 support and service, because at liberty mutual insurance, we believe our customers do their best out there in the world, so we do everything we can to be there for them when they need us. plus, you could save hundreds when you switch, up to $423. call... today. liberty mutual insurance -- responsibility. what's your policy?

we've got a raging bull market in biotech right now. also some of the smaller more speculative players seem to be getting taken over left and right. tonight i want to circle back to another cramer famed biotech speck, that's acorda therapeutic. its big drug is impura, which helps multiple sclerosis patients begin to regain some ability to walk. a speculative drug like this is more about the pipeline than the earnings. just last june dramatically outperformed the s&p 500, up 18% since we interviewed them back in mid april. let take a closer look with dr.

ron cohen to find out more about the company. welcome back to "mad money." >> thanks very much. >> i do call it speculative. i'm always concerned you've got a lot in the pipe that hasn't been approved, includes things that are really still early on. we know impura is being used for m.s. strokes, cerebral palsy, those could be huge but i don't want people to think it's going to happen in the next few month. >> what's most encouraging, we've done some clinical studies in human beings with post-stroke and we saw improvement in walking, which is a huge issue for people post-stroke and we're currently selling it to people with m.s. to improve walking. we have designed the next clinical study for people in post-stroke, we're going to talk to the fda about it, get an agreement and hopefully by the second quarter of ' 14, we'll

start that clinical trial. if that goes good, we'll be on our way hopefully on getting it to people with strokes. >> people are probably wondering, stroke victims or their loved ones i want to be in the test, i want to be in the test, why can't we do it in october? what takes so long? what happens between now and the second quarter? >> for us between now we have a new formulation of the drug that we think will have some advantages for patients so we're going to finish that formulation. we also need to talk to the fda so we're talking about a matter of a few months but in exchange we'll have a new formulation that we hope will be even better for new patients. >> we've been watching some of the evolutions of the biogen drugs. some of these formulations are some of the reasons that impura

is doing well. >> impura is unique. it is not like all the other ms drugs. those are called disease modifying drugs. but you can potentially take impura together with one of those drugs. >> how many people are doing that? what's the percentage of people taking impura versus who could take it? >> over 80,000 people with m.a.s. have tried the drug since we launched it. we think there are another 20,000 or so who have walking impairment and who haven't tried it and ought to give it a try. >> is that because doctors don't know about it, they're afraid or -- >> the doctors almost 100% know about it. we have a very good understanding moamong the docto. it's really among the patients and their care givers. there are so many new drugs

coming for ms, it takes time to sort through what is this one for, what is that one for? >> let's talk about the neuropathic pain assets acquisition and what that means for you. not a lot of money involved but it's a big market. >> neuropathic pain is basically pain in your nerves and they're shooting this horrible burning pain into your brain and you can feel it, even though you don't see it. people with diabetes get it a lot, people who have chemotherapy for cancer get it a lot. the product we brought in is a patch -- >> is it like this? this is capsazin. >> the patch is a much stronger application. >> why wouldn't anyone who has pain want this? why is it limited to the nerve?

>> when you develop therapy, you have to do clinical trials for a particular thing. you go to the fda and say we have proof for this particular thing. >> i have this because i use this. it's not as effective as i would like. if there was something that really did blunt the pain that was not addictive, it would be one of the biggest sellers in the world. >> and we would have to do those clinical trials for that kind of pain. we're interested in looking particularly next at die babeti pain. people with diabetes get that pain a lot and if it could help them, that's huge. >> these are big market, post-stroke, almost as big as m.s. >> we estimate there are as many as 3 million people who have had stroke and have walking problems. >> this stock remains to me one of the best you should be looking at. this is dr. ron cohen, president of acorda therapeutics, delivering on the numbers. and still a little room before

it gets to its 52-week high again. stay with cramer. [ male announcer ] it's time. time to have new experiences with a familiar keyboard. to update our status without opening an app. to have all our messages in one place. to browse... and share... faster than ever. ♪ it's time to do everything better than before. the new blackberry q10. it's time. a talking car. but i'll tell you what impresses me. a talking train. this ge locomotive can tell you exactly where it is, what it's carrying, while using less fuel. delivering whatever the world needs, when it needs it.

♪ after all, what's the point of talking if you don't have something important to say? ♪

this market is so red hot that it does make me pause but i

got to tell you something, when you see the kinds of quarters we saw today, shoot the lights out when you get a great number from china, great number from europe and america, the back drop is so compelling. i'm jim cramer and i will see you tomorrow! record highs again for the dow. no taper from the fed. hold everything. tom's jobs report comes out. we will see if that changes anything. on capitol hill meanwhile, the obama care battle is raging. question -- should obama care opponents focus on defunding the plan or make work harder at getting the individual mandate repealed? senator ted cruz joins us exclusively to tell us about his strategy. >> and then russia spits in